1. Home
  2. MBWM vs LTGO Comparison

MBWM vs LTGO Comparison

Compare MBWM & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBWM

Mercantile Bank Corporation

SELL

Current Price

$60.21

Market Cap

1.1B

Sector

Finance

ML Signal

SELL

Logo Latigo Biotherapeutics Inc. Common Stock

LTGO

Latigo Biotherapeutics Inc. Common Stock

SELL

Current Price

$12.64

Market Cap

924.9M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
MBWM
LTGO
Founded
1997
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
924.9M
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
MBWM
LTGO
Price
$60.21
$12.64
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
★ $64.17
$52.25
AVG Volume (30 Days)
99.0K
★ 248.5K
Earning Date
10-20-2026
11-05-2026
Dividend Yield
★ 2.64%
N/A
EPS Growth
★ 10.95
N/A
EPS
★ 4.21
N/A
Revenue
N/A
N/A
Revenue This Year
$16.34
N/A
Revenue Next Year
$7.39
N/A
P/E Ratio
$14.37
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.40
$10.24
52 Week High
$63.41
$25.93

Technical Indicators

Market Signals
Indicator
MBWM
LTGO
Relative Strength Index (RSI) 49.24 37.24
Support Level $56.97 $10.24
Resistance Level $62.64 $15.95
Average True Range (ATR) 1.40 1.64
MACD -0.03 0.02
Stochastic Oscillator 16.29 37.38

Price Performance

Historical Comparison
MBWM
LTGO

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: